Economic evidence in anxiety disorders: A review

被引:15
|
作者
Löthgren M. [1 ]
机构
[1] Centre for Health Economics, Stockholm School of Economics, Stockholm
关键词
Public Health; Anxiety Disorder; Economic Evidence;
D O I
10.1007/s10198-005-0284-3
中图分类号
学科分类号
摘要
Based on this literature review, one obvious conclusion is that there are currently big gaps in the available literature regarding the costs of anxiety disorders in Europe. Very few studies reporting cost estimates were found. Only two studies in total were found for GAD, one from France and one from Hungary. Only one Spanish study was found for panic disorder. No studies were found for the other anxiety disorders. The reviewed studies reveal some cost patterns in France (for GAD) for patients with and without comorbidities and for Spain for panic disorder patients; but from a European-wide perspective, based on these scarce findings, the lack of available data makes it difficult, if not impossible, to use the identified data to extrapolate the costs in countries where no studies/data were found. The only conclusion that can be made regarding this is the clear need for more research in this area, both in the Western European countries as well as in the Central and Eastern European countries.
引用
收藏
页码:S20 / S25
页数:5
相关论文
共 50 条
  • [1] Review: Economic evidence of preventive interventions for anxiety disorders in children and adolescents - a systematic review
    Anna-Kaisa, Vartiainen
    Virpi, Kuvaja-Kollner
    Mervi, Rantsi
    Elisa, Rissanen
    Terhi, Luntamo
    Marjo, Kurki
    Andre, Sourander
    Eila, Kankaanpaa
    CHILD AND ADOLESCENT MENTAL HEALTH, 2022, 27 (04) : 378 - 388
  • [2] Economic burden of anxiety disorders: a review
    Martin, P
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 1998, 24 (03): : 280 - 296
  • [3] Economic evidence of preventive interventions for anxiety disorders in children and adolescents - a systematic review
    Vartiainen, A. -K.
    Kuvaja-Kollner, V.
    Rantsi, M.
    Rissanen, E.
    Luntamo, T.
    Kurki, M.
    Sourander, A.
    Kankaanpaa, E.
    EUROPEAN PSYCHIATRY, 2022, 65 : S684 - S684
  • [4] Economic evidence in psychotic disorders: A review
    Löthgren M.
    The European Journal of Health Economics, 2004, 5 (Suppl 1) : S67 - S74
  • [5] Economic evidence in affective disorders: A review
    Löthgren M.
    The European Journal of Health Economics, 2004, 5 (Suppl 1) : S12 - S20
  • [6] Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review
    Stanciu, Corneliu N.
    Brunette, Mary F.
    Teja, Nikhil
    Budney, Alan J.
    PSYCHIATRIC SERVICES, 2021, 72 (04) : 429 - 436
  • [7] Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
    Pae, Chi-Un
    Serretti, Alessandro
    Patkar, Ashwin A.
    Masand, Praksh S.
    CNS DRUGS, 2008, 22 (05) : 367 - 388
  • [8] The role of anticonvulsant drugs in anxiety disorders - A critical review of the evidence
    Mula, Marco
    Pini, Stefano
    Cassano, Giovanni B.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (03) : 263 - 272
  • [9] Economic costs of anxiety disorders
    DuPont, RL
    Rice, DP
    Miller, LS
    Shiraki, SS
    Rowland, CR
    Harwood, HJ
    ANXIETY, 1996, 2 (04): : 167 - 172
  • [10] Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis
    Konnopka, Alexander
    Koenig, Hannah
    PHARMACOECONOMICS, 2020, 38 (01) : 25 - 37